Investor Relations
Investment Highlights
STDCO is positioned to capture the explosive growth in crypto-medical treatments.
$2.1B
Market Cap
420%
YoY Growth
69M
Addressable Market
27
Pipeline Treatments
Explosive Market Growth
The Solana Transmitted Disease market is projected to reach $420B by 2030, with STDCO positioned as the clear market leader.
First-Mover Advantage
We're the only pharmaceutical company exclusively focused on crypto-related medical conditions, giving us an unassailable competitive moat.
Proven Leadership
Our executive team combines decades of pharmaceutical experience with deep crypto market knowledge.
Financial Performance
Consistent growth across all key metrics demonstrates our strong execution.
Q3 2025 Highlights
Revenue$420M (+69% YoY)
Gross Margin84.2%
R&D Investment$126M
Cash Position$1.2B
Upcoming Events
Stay informed about our latest developments and investor communications.
Q4 2025 Earnings Call
January 15, 2026
4:30 PM ESTJoin CEO Dr. Chad Pumpalot and CFO Diamond Handsworth for our quarterly results presentation and Q&A session.
JP Morgan Healthcare Conference
January 13-16, 2026
San Francisco, CADr. Pumpalot will present STDCO's vision for the future of crypto-medical treatments at this premier healthcare investment conference.
Annual Shareholder Meeting
May 20, 2026
Virtual EventVote on key company matters and hear directly from leadership about our strategic direction and pipeline progress.
Investor Resources
Access all the information you need to make informed investment decisions.
Annual Report
Comprehensive overview of our 2025 performance
SEC Filings
All regulatory filings and disclosures
Stock Information
Real-time quotes and historical data
Analyst Coverage
Research reports and price targets
Investor Relations Contact
Have questions about STDCO's investment opportunity? Our IR team is here to help.